SEC Form 4 · accession 0001638643-26-000028
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel Patrick O'Day
Officer — Chairman & CEO · Director
Period of report
Aug 3, 2026
Accepted (ET)
Aug 4, 2026 · 5:40 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0000882095
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Aug 3, 2026 | S | 6,700 | $129.6583 | D | 600,433 | D | |
| Common StockF3 | Aug 3, 2026 | S | 7,700 | $130.8022 | D | 592,733 | D | |
| Common StockF4 | Aug 3, 2026 | S | 600 | $131.3433 | D | 592,133 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2026.
- F2Sale prices for the transactions reported range from $129.17 to $130.16. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
- F3Sale prices for the transactions reported range from $130.18 to $131.17. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
- F4Sale prices for the transactions reported range from $131.21 to $131.47. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.